Serina Therapeutics SEC Filings

Serina Therapeutics, Inc. Chief Scientific Officer Randall Moreadith reported option exercises and stock sales in mid-January 2026. On January 13, 2026, he exercised stock options to acquire 5,416 shares of Serina common stock at an exercise price of $0.06 per share, then sold 5,416 shares at a weighted average price of $2.50 per share. On January 14, 2026, he exercised options for an additional 1,084 shares at $0.06 per share and sold 1,084 shares at a weighted average price of $2.5031 per share, leaving him with no directly held common stock after these transactions.

Following the reported transactions, Moreadith beneficially owned 332,686 stock options with an exercise price of $0.06 per share, expiring on May 6, 2031, and the filing notes that these stock options are fully vested.

Serina Therapeutics Chief Scientific Officer reports option exercise and sale of shares. On 01/08/2026, Randall Moreadith exercised stock options for 13,000 shares of Serina Therapeutics, Inc. common stock at an exercise price of $0.06 per share. On the same date, he sold 13,000 shares of common stock at a weighted average price of $2.6887 per share, with individual sale prices ranging from $2.85 to $2.60. Following these transactions, he reported owning no shares of common stock directly and 339,186 stock options, which the filing states are fully vested.

Serina Therapeutics reported an insider equity transaction by its Chief Scientific Officer, Randall Moreadith. On 12/23/2025, he exercised a stock option to buy 4,100 shares of common stock at an exercise price of $0.06 per share, then sold 4,100 shares of common stock at a sale price of $2.6 per share on the same date.

After this transaction, he continued to hold 352,186 stock options directly, each with an exercise price of $0.06 and an expiration date of 05/06/2031. The filing notes that these stock options are fully vested, meaning they are already earned and exercisable under the plan terms.

Serina Therapeutics, Inc. reported an insider transaction by its Chief Scientific Officer on 12/22/2025. The officer exercised a stock option to buy 5,673 shares of common stock at an exercise price of $0.06 per share and on the same day sold 5,673 shares at a weighted average price of $2.6737 per share. The sale price reflects multiple trades at prices ranging from $2.705 to $2.66. After these transactions, the reporting person held 0 shares of common stock directly but continued to hold 356,286 stock options, which are fully vested and exercisable for common stock until 05/06/2031.

Serina Therapeutics Chief Scientific Officer Randall Moreadith exercised stock options and immediately sold the resulting shares. On 12/16/2025, he exercised 3,227 stock options at an exercise price of $0.06 per share, receiving the same number of common shares. He then sold all 3,227 shares at a weighted average price of $2.9631 per share in multiple trades between $3.00 and $2.96, leaving him with 0 shares of common stock held directly.

Following this transaction, Moreadith continues to hold 361,959 stock options with an exercise price of $0.06 per share, which are fully vested and expire on 05/06/2031.

Serina Therapeutics, Inc.'s Chief Scientific Officer, Randall Moreadith, reported insider equity transactions dated 12/12/2025. He acquired 1,700 shares of common stock at $0.06 per share and, on the same date, sold 1,700 shares at a weighted average price of $3.2597, with sale prices ranging from $3.25 to $3.275. After these transactions, he directly held 0 shares of common stock.

The report also lists a stock option (right to buy) with an exercise price of $0.06 per share, covering 1,700 underlying shares in this transaction and expiring on 05/06/2031. Following the activity, 365,186 derivative securities (stock options) are shown as beneficially owned, and the stock options are described as fully vested.

Serina Therapeutics, Inc. insider trading report: the company’s Chief Scientific Officer exercised a stock option for 3,555 shares of common stock at an exercise price of $0.06 per share on 12/11/2025 and sold the same 3,555 shares the same day. The reported sale had a weighted average price of $3.2404 per share, based on multiple trades between $3.20 and $3.35. After these transactions, the reporting person held no shares of common stock directly but continued to hold 366,886 stock options that remain fully vested.

Serina Therapeutics, Inc. reported insider stock transactions by its Chief Scientific Officer on a Form 4. On December 9, 2025, the officer exercised stock options to buy 600 shares of common stock at an exercise price of $0.06 per share, then sold 600 shares at a weighted average price of $3.3133 per share, with individual sale prices ranging from $3.31 to $3.315. On December 10, 2025, the officer similarly exercised options for 645 shares at $0.06 per share and sold 645 shares at $3.35 per share.

The filing shows these transactions as direct ownership and notes that the related stock options, which carry an exercise price of $0.06 and expire on May 6, 2031, are fully vested. After the reported option exercises, the officer holds 370,441 stock options with the same exercise price.

Serina Therapeutics, Inc. reported that it has submitted a complete response to the U.S. Food and Drug Administration’s clinical hold letter for SER-252, its lead program for advanced Parkinson's disease. The company disclosed that the FDA’s clinical hold letter for SER-252 was dated November 25, 2025, and that its response was submitted on December 10, 2025. Serina also issued a press release on this regulatory update, which is included as an exhibit to the report and incorporated by reference.